Holen Sie sich die Stockscreener-App
3.16
4.53%
-0.15
Handel nachbörslich:
3.18
0.02
+0.63%
Schlusskurs vom Vortag:
$3.31
Offen:
$3.3
24-Stunden-Volumen:
10.46M
Relative Volume:
0.52
Marktkapitalisierung:
$1.69B
Einnahmen:
$66.41M
Nettoeinkommen (Verlust:
$-559.78M
KGV:
-2.6285
EPS:
-1.2022
Netto-Cashflow:
$-328.09M
1W Leistung:
-1.86%
1M Leistung:
-5.39%
6M Leistung:
-9.46%
1J Leistung:
-43.97%
1-Tages-Spanne:
$3.14
$3.305
1-Wochen-Bereich:
$3.14
$3.42
52-Wochen-Spanne:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.16 | 1.76B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - marketbeat.com
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19% - simplywall.st
Recursion Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-08-09 - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen - marketbeat.com
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.st
Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Recursion Pharmaceuticals Inc (RXRX) Stock Analysis & Forecast - TradingKey
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocus
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals Insiders Sell US$790k Of Stock, Possibly Signalling Caution - Moomoo
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value - simplywall.st
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS - marketbeat.com
Recursion Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Recursion Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Recursion misses Q2 2026 revenue forecast, shares fall premarket - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak Earnings - marketbeat.com
Recursion Pharmaceuticals Shares Fall After Q2 Miss - marketscreener.com
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update - Yahoo Finance
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q2 Revenue $7.7M - marketscreener.com
Recursion Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Recursion Pharmaceuticals 2026: Revenue $7.67M, EPS ($0.25) — 10-Q Summary - TradingView
Recursion Pharmaceuticals (NASDAQ: RXRX) gains Genentech milestone, highlights FAP drug progress - Stock Titan
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q2 2026 -- GF Value Sees 43% Upside - GuruFocus
Recursion Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Recursion Pharmaceuticals in focus as earnings test AI promise By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals in focus as earnings test AI promise - Investing.com
Renaissance Technologies LLC Makes New $7.37 Million Investment in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX): Investor Outlook on a Biotech Pioneer with 127.99% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):